NCT06049186 is a NA clinical trial of CRD in Polycystic Ovary Syndrome, sponsored by Shanghai First Maternity and Infant Hospital.

Who is sponsoring NCT06049186?

NCT06049186 is sponsored by Shanghai First Maternity and Infant Hospital.

What drugs are being tested in NCT06049186?

Interventions in NCT06049186: CRD, Metformin.

What condition does NCT06049186 study?

NCT06049186 studies Polycystic Ovary Syndrome.

Is NCT06049186 still recruiting?

NCT06049186 is currently status unknown. Last updated 22 September 2023.

Last reviewed 2023-09-22 · How we verify

NCT06049186

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CRD vs. Met in Patients With Obese PCOS Infertility

Status unknown NA Last updated 22 September 2023

What this trial tests

NA trial testing CRD in Polycystic Ovary Syndrome in 406 participants. Status unknown.

Timeline

15 September 2023

Primary endpoint
1 January 2026

31 March 2026

Quick facts

Lead sponsor	Shanghai First Maternity and Infant Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	406
Start date	15 September 2023
Primary completion	1 January 2026
Estimated completion	31 March 2026
Sites	1 location across China

Drugs / interventions tested

CRD
Metformin (metformin) — full drug profile →

Conditions studied

Polycystic Ovary Syndrome — all drugs for Polycystic Ovary Syndrome →

Sponsor

Shanghai First Maternity and Infant Hospital

Who can join

Adults 20 to 40, female only, with Polycystic Ovary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disease and a major cause of anovulatory infertility in reproductive-aged women. From 2010 to 2020, it was found that the prevalence of PCOS in reproductive-aged women in China reached 7.8%, an increase of 65% over 10 years ago. Many of them are overweight or obese. Weight loss including diet modifications can significantly reduce reproductive and metabolic disorders of PCOS and is recommended as a first step in the treatment of overweight or obese women with PCOS. Many weight loss programs have been proposed, including calorie-restriction diet (CRD) intervention. Whether CRD intervention prior to ovulation induction therapy could improve live birth rates in overweight/obese PCOS women has not been illustrated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Polycystic Ovary Syndrome

Currently open trials in the same condition.

NCT07591246 — Efficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction · NA · recruiting
NCT07446985 — Is There a Benefit From Addition of Physical Exercise to Diet Restriction/Limitation in PCOS Women With Asthma? · NA · recruiting
NCT07385716 — Evaluation of the Effect of Time-Restricted Feeding and Mediterranean Diet Model in Women With Polycystic Ovary Syndrome · NA · recruiting
NCT07366944 — PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes · NA · recruiting
NCT07289399 — Is There a Benefit From Addition of Treadmill Walking to Diet Restriction in Psoriasis Women With PCOS? · NA · recruiting

Other Shanghai First Maternity and Infant Hospital trials

Trials by the same sponsor.

NCT07426146 — Feasibility Effects of a Low-GI, High-fibre Diet in PCOS: a Prospective Cohort Study in Remote Yunnan · recruiting
NCT06093984 — Cumulative Live Birth Rates in Dual Ovarian Stimulation Versus Two Antagonist Stimulations in Poor Ovarian Responders · NA · not yet recruiting
NCT06096805 — Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR) · recruiting
NCT06104748 — A Cohort of Maternal Vascular Malperfusion-related FGR (CoMVMFGR) · recruiting
NCT05498558 — The Selection of Pregnancy for Patients After Tubal Ectopic Pregnancy Treatment · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06049186 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai First Maternity and Infant Hospital
Last refreshed: 22 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06049186.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing